Latest SMN2 Stories
- PTC Therapeutics to Receive $10 Million Milestone Payment from Roche - SOUTH PLAINFIELD, N.J., Nov. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc.
-Results published in Science show small molecule SMN2 splicing modifiers to be effective in SMA mouse models- SOUTH PLAINFIELD, N.J., Aug.
WALTHAM, Mass., Dec. 15, 2010 /PRNewswire/ -- Repligen Corporation (Nasdaq: RGEN) today announced that the Company has received $1,400,000 in research funding from the Muscular Dystrophy Association ("MDA") to support the ongoing development of RG3039 for Spinal Muscular Atrophy ("SMA").
The devastating, currently incurable motor-neuron disease spinal muscular atrophy (SMA) might soon be treated with tiny, chemically modified pieces of RNA called antisense oligonucleotides (ASOs).
A chemical cousin of the common antibiotic tetracycline might be useful in treating spinal muscular atrophy (SMA), a currently incurable disease that is the leading genetic cause of death in infants.
WALTHAM, Mass., Oct.
Spinal Muscular Atrophy is the second-leading cause of infant mortality in the world.
- Sleep; the state or condition of being asleep.